ڕۆشەنی کورد

نرخەکانی بازاڕ:

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] $53.92: کڕین: 53.92 | فرۆشتن: 53.92 IQD

[هەولێر] 0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] ئۆنسەی زیو: کڕین: | فرۆشتن: IQD

[هەولێر] دینار: کڕین: | فرۆشتن: IQD

[هەولێر] 167,750: کڕین: 167,750 | فرۆشتن: 167,750 IQD

[هەولێر] 0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] $4055.99: کڕین: 4055.99 | فرۆشتن: 4055.99 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] ئۆنسە: کڕین: | فرۆشتن: IQD

[هەولێر] نرخە جیهانییەکان: کڕین: | فرۆشتن: IQD

[هەولێر] 414,862: کڕین: 414,862 | فرۆشتن: 414,862 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٩: کڕین: ٩ | فرۆشتن: ٩ IQD

[هەولێر] 645,340: کڕین: 645,340 | فرۆشتن: 645,340 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ١٤: کڕین: ١٤ | فرۆشتن: ١٤ IQD

[هەولێر] 829,723: کڕین: 829,723 | فرۆشتن: 829,723 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ١٨: کڕین: ١٨ | فرۆشتن: ١٨ IQD

[هەولێر] 1,014,106: کڕین: 1,014,106 | فرۆشتن: 1,014,106 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٢٢: کڕین: ٢٢ | فرۆشتن: ٢٢ IQD

[هەولێر] 968,011: کڕین: 968,011 | فرۆشتن: 968,011 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٢١: کڕین: ٢١ | فرۆشتن: ٢١ IQD

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] $53.92: کڕین: 53.92 | فرۆشتن: 53.92 IQD

[هەولێر] 0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] ئۆنسەی زیو: کڕین: | فرۆشتن: IQD

[هەولێر] دینار: کڕین: | فرۆشتن: IQD

[هەولێر] 167,750: کڕین: 167,750 | فرۆشتن: 167,750 IQD

[هەولێر] 0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] دۆلار: کڕین: | فرۆشتن: IQD

[هەولێر] $4055.99: کڕین: 4055.99 | فرۆشتن: 4055.99 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] ئۆنسە: کڕین: | فرۆشتن: IQD

[هەولێر] نرخە جیهانییەکان: کڕین: | فرۆشتن: IQD

[هەولێر] 414,862: کڕین: 414,862 | فرۆشتن: 414,862 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٩: کڕین: ٩ | فرۆشتن: ٩ IQD

[هەولێر] 645,340: کڕین: 645,340 | فرۆشتن: 645,340 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ١٤: کڕین: ١٤ | فرۆشتن: ١٤ IQD

[هەولێر] 829,723: کڕین: 829,723 | فرۆشتن: 829,723 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ١٨: کڕین: ١٨ | فرۆشتن: ١٨ IQD

[هەولێر] 1,014,106: کڕین: 1,014,106 | فرۆشتن: 1,014,106 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٢٢: کڕین: ٢٢ | فرۆشتن: ٢٢ IQD

[هەولێر] 968,011: کڕین: 968,011 | فرۆشتن: 968,011 IQD

[هەولێر] +0.00%: کڕین: 0.00 | فرۆشتن: 0.00 IQD

[هەولێر] عەیار ٢١: کڕین: ٢١ | فرۆشتن: ٢١ IQD

گەڕانەوە بۆ هەواڵەکان

سۆرانی کرمانجی عربي فارسی English

WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

2026-10-26

WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation. These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.

Solidarity trial investigators will interrupt the trials with immediate effect. For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial.

These will also be reported in the peer-reviewed publication. This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.

گەڕانەوە بۆ پەڕەی سەرەکی